Menu
← Oncology Approval Tracker
FDA DECISION ·
Truqap + fulvestrant
capivasertib + fulvestrant · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer and a qualifying PIK3CA, AKT1, or PTEN alteration after progression on endocrine therapy for metastatic disease or recurrence during or within 12 months after adjuvant therapy.
LAMPGEN ANALYSIS
Why it matters
The approved regimen links AKT inhibition to a defined molecular subset following endocrine treatment.
What research teams should watch
Capture the assay, alteration, prior endocrine treatment, and timing of recurrence before making eligibility determinations.
PRIMARY RECORDS